91%Confidence
0Views
FDASource
2026-03-02Date
Summary
Fresenius Kabi's vancomycin HCl recall represents the third sterility assurance failure from the same facility, confirming systemic quality control breakdowns. This pattern suggests inadequate aseptic processing validation that may require complete manufacturing process reevaluation.
Actionable: Monitor Fresenius Kabi for potential FDA warning letters or consent decrees related to their compounding facility's repeated sterility failures.
AI Confidence: 91%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productvancomycin HCl, 1.5 grams, 1.5 grams added to 500 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now